Cornerstone Select Advisors LLC Sells 3,298 Shares of TG Therapeutics, Inc. $TGTX

Cornerstone Select Advisors LLC lessened its position in TG Therapeutics, Inc. (NASDAQ:TGTX) by 5.9% during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 53,004 shares of the biopharmaceutical company’s stock after selling 3,298 shares during the quarter. TG Therapeutics makes up about 1.7% of Cornerstone Select Advisors LLC’s portfolio, making the stock its 18th biggest position. Cornerstone Select Advisors LLC’s holdings in TG Therapeutics were worth $1,908,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of TGTX. Rhumbline Advisers raised its holdings in shares of TG Therapeutics by 6.0% in the second quarter. Rhumbline Advisers now owns 404,660 shares of the biopharmaceutical company’s stock valued at $14,564,000 after purchasing an additional 22,806 shares during the last quarter. Franklin Resources Inc. grew its position in TG Therapeutics by 25.3% in the second quarter. Franklin Resources Inc. now owns 91,387 shares of the biopharmaceutical company’s stock valued at $3,289,000 after purchasing an additional 18,452 shares in the last quarter. DNB Asset Management AS increased its stake in TG Therapeutics by 47.8% in the 2nd quarter. DNB Asset Management AS now owns 10,527 shares of the biopharmaceutical company’s stock valued at $379,000 after buying an additional 3,406 shares during the last quarter. Inspire Advisors LLC bought a new stake in TG Therapeutics during the 2nd quarter worth about $202,000. Finally, Persistent Asset Partners Ltd boosted its stake in shares of TG Therapeutics by 137.2% during the 2nd quarter. Persistent Asset Partners Ltd now owns 85,580 shares of the biopharmaceutical company’s stock worth $3,080,000 after buying an additional 49,508 shares during the last quarter. Institutional investors and hedge funds own 58.58% of the company’s stock.

Analyst Ratings Changes

A number of analysts recently issued reports on the company. HC Wainwright began coverage on TG Therapeutics in a research report on Monday, October 6th. They issued a “buy” rating and a $60.00 target price on the stock. Wall Street Zen upgraded TG Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, November 8th. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of TG Therapeutics in a research report on Wednesday. B. Riley upgraded TG Therapeutics to a “strong-buy” rating in a research note on Tuesday, November 4th. Finally, JPMorgan Chase & Co. raised their target price on shares of TG Therapeutics from $46.00 to $49.00 and gave the company an “overweight” rating in a research note on Monday, November 3rd. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, TG Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $50.25.

TG Therapeutics Price Performance

Shares of NASDAQ TGTX opened at $31.95 on Friday. The company has a quick ratio of 2.96, a current ratio of 3.86 and a debt-to-equity ratio of 0.89. The business’s 50 day moving average price is $33.78 and its two-hundred day moving average price is $33.94. The company has a market cap of $5.07 billion, a PE ratio of 86.35 and a beta of 1.95. TG Therapeutics, Inc. has a twelve month low of $25.28 and a twelve month high of $46.48.

TG Therapeutics (NASDAQ:TGTX) last issued its earnings results on Monday, November 3rd. The biopharmaceutical company reported $2.43 EPS for the quarter, topping the consensus estimate of $0.24 by $2.19. The company had revenue of $161.71 million during the quarter, compared to the consensus estimate of $152.12 million. TG Therapeutics had a return on equity of 26.05% and a net margin of 13.31%.The firm’s revenue for the quarter was up 92.7% compared to the same quarter last year. During the same period in the previous year, the company posted $0.02 EPS. TG Therapeutics has set its FY 2025 guidance at EPS. On average, analysts predict that TG Therapeutics, Inc. will post 0.08 EPS for the current year.

Insider Activity at TG Therapeutics

In other TG Therapeutics news, Director Sagar Lonial sold 20,852 shares of the company’s stock in a transaction on Thursday, September 11th. The shares were sold at an average price of $32.24, for a total value of $672,268.48. Following the transaction, the director directly owned 94,061 shares in the company, valued at $3,032,526.64. The trade was a 18.15% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 10.64% of the stock is currently owned by corporate insiders.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.